ArticleJournal of the Pediatric Infectious Diseases Society2025
Hospitalizations Associated With Respiratory Syncytial Virus Illness Among Children and Adolescents in Ontario, Canada.
Article in Journal of the Pediatric Infectious Diseases Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Respiratory Syncytial Virus-Related Hospitalizations Among Infants Receiving Nirsevimab.JAMA network open · 2026Article
- Acute Respiratory Tract Infections and Severe Disease Among Hospitalized Children.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) illness poses a significant burden in children yet is understudied in those >2 years old.
methodsWe identified patients aged ≤17 years hospitalized with RSV between July 2010 and March 2023 using Ontario's administrative healthcare data. RSV-specific hospitalizations were defined by ICD-10-CA codes (B97.4, J12.1, J20.5, J21.0) and included overnight stays. Key outcomes included hospitalization frequency, intensive care unit (ICU) use, mechanical ventilation, supplemental oxygen, length of stay, mortality, and costs. Risk conditions included chronic respiratory diseases, congenital malformations, and cystic fibrosis.
resultsThere were 23 930 RSV hospitalizations; annual counts ranged from 1356 (2010-2011) to 4298 (2022-2023). Children <2 years accounted for 84% of hospitalizations, though risk conditions were more common in those aged 2-17 years (35% vs. 7%). In 2022-2023, hospitalizations were ~2-fold, ~3-fold, and ~5-fold higher than previous years (2010-2021) for those <12 months, 12-<24 months, and 2-17 years, respectively. Median length of stay was 69 h. Annual median cost per hospitalization was $5070 (IQR: $4486-6742). ICU admission occurred in 12% of cases, with median costs over twice that of non-ICU stays ($12 042 vs. $5070). ICU use ranged from 7% to 16% in <2 years and 10%-35% in 2-17 years. In-hospital mortality was 0.12%, higher among those with risk conditions (<2 years: 0.61%; 2-17 years: 1.02%).
conclusionsThis study highlighted the burden associated with RSV hospitalizations for people aged ≤17 years and those who may be more impacted by RSV illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.